Defendant Name: Northwest Biotherapeutics, Inc.

Defendant Type: Public Company

Document Reference: 34-87281-s

Document Details

Legal Case Name In the Matter of Northwest Biotherapeutics, Inc.
Document Name SEC Files Settled Action Against Biotechnology Company Related to Unremediated Material Weaknesses Spanning Twelve Years
Document Date 10-Oct-2019
Document Format Administrative Proceeding
File Number 3-19582
Allegation Type Issuer Reporting and Disclosure
Document Summary The SEC stated that: "[It] filed a settled action against Northwest Biotherapeutics (NWBO) for failing to maintain internal control over financial reporting (ICFR) for twelve consecutive annual reporting periods. In each of its annual Form 10-K filings with the Commission over more than a decade, NWBO disclosed material weaknesses, many of which recurred year after year, with insufficient effort at remediation."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Compliance Related Independent Consultant
Monetary Penalties:

Civil Penalty

Individual:     $250,000.00 Shared:    

Related Documents:

34-87281 10-Oct-2019 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing and Cease-and-Desist Order
On October 10, 2019, the SEC instituted settled cease-and-desist proceedings against Northwest Biotherapeutics, Inc. ("Respondent"). The SEC stated: "These proceedings involve violations of the federal securities laws in connection with the Respondent's Internal Control over Financial Reporting ("ICFR"). Respondent failed to create and implement effective ICFR for twelve consecutive annual reporting periods from 2007 through 2018."